CNN data guru dubs Trump the ‘most influential president this century'
Enten argued that the president 'has been tremendously influential to a historic degree' just over half a year into his second term.
'Love it, like it, lump it — Trump's remaking the United States of America,' Enten said as he began a weekend segment on the cable news network. 'I can't think of a more influential president during this century.'
Enten noted that the highest average US tariff rate in effect on another country has jumped from 2% last year up to about 18%, which is the largest rate in America since the 1930s.
3 CNN data guru Harry Enten cited President Trump's work on tariffs, immigration and executive orders to back up his assessment of 'historic' influence of the commander in chief.
CNN
3 Trump has made overhauling US trade a key objective of his second term.
AFP via Getty Images
On immigration, the data buff noted that net migration into the US appears to be trending down sharply, by at least 60%, from 2.8 million last year.
'We may be dealing with — get this — negative net migration to the United States in 2025,' Enten said. 'That would be the first time there is negative net migration in this country in at least 50 years.'
'Trump has always run on tariffs, and he's running a hawkish line on immigration,' Enten said. 'And on both of those issues — we are seeing record-high tariff rates for this century, and when it comes to immigration, net migration, we are seeing record low levels.'
3 The president has also mounted a significant clampdown at the US-Mexico border and stepped up enforcement of immigration laws.
REUTERS
Based on those two factors, Enten contended that Trump is the most influential president 'probably dating a good [chunk back] into the 20th century.'
Another example Enten cited was Trump's use of executive orders, having signed 180 of them halfway through his first year of his second term, surpassing all of his predecessors dating back to Franklin D. Roosevelt.
Trump is one of two presidents to serve two nonconsecutive terms as president, alongside Grover Cleveland.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
USI Insurance Services buys Rogers Insurance Centre
USI Insurance Services has acquired Rogers Insurance Centre, a brokerage based in Miami, Oklahoma, US. Financial details of the transaction were not made public. Set up in 1997, Rogers Insurance Centre offers commercial and personal risk insurance programmes. Commenting on the acquisition, Rogers Insurance Centre vice-president and co-owner Devony Metcalf stated: 'For more than 25 years, our agency has built a strong reputation for providing innovative risk management solutions tailored to the needs of businesses and individuals across Oklahoma, including Tribal Governments and their business enterprises. 'This exciting partnership with USI represents a significant milestone for our team and reinforces our continued dedication to delivering client-focused solutions that will benefit our current and future clients.' USI provides a range of services such as property and casualty, employee benefits and personal risk management. The brokerage serves risk management clients, large corporations, mid-sized companies and individual policyholders. USI regional CEO Evan Simmons said: 'We are thrilled to welcome Devony and the exceptional team of professionals from Rogers Insurance Centre to the USI family. Together, we look forward to building on their strong reputation for service and innovation as we expand USI's commercial and personal risk expertise in Oklahoma and beyond.' The company employs more than 10,500 professionals across roughly 200 offices. USI ONE, its proprietary platform, combines analytics, networked resources and strategic planning to offer tailored solutions. "USI Insurance Services buys Rogers Insurance Centre " was originally created and published by Life Insurance International, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
6 minutes ago
- Yahoo
New US-EU trade deal on tariffs ends pharma's geopolitical immunity
For the first time in decades, the pharmaceutical industry has been directly affected by a geopolitical trade negotiation between the US and the EU. On 27 July, the US government announced a 15% tariff on branded pharmaceutical products imported from the EU. Despite the decrease from the original 30% tariff on pharmaceuticals earlier in the year, this disrupts a long-established practice of the exemption of medicines from tariffs due to their importance in public health. The 15% tariff is not expected to happen immediately as implementation will be dependent on a National Security investigation regarding pharmaceutical imports. This trade deal puts the pharmaceutical industry at risk of losing between $13bn and $19bn, with consequences that extend beyond short-term financials. It will force pharmaceutical companies to make a tradeoff between tightening their profit margins and increasing drug prices, with both paths posing a risk to patient access and payer relations. The imposition of tariffs threatens to elevate costs across the pharmaceutical value chain, and could lead to a substantial increase in drug development costs, manufacturing, and distribution, with global supply chains for active pharmaceutical ingredients (APIs), raw materials, and equipment directly exposed. This disruption could create uncertainty in launch planning, particularly for late-stage assets with EU-based manufacturing and production planned for US entry. Companies manufacturing pharmaceutical products in Europe will need to anticipate financial exposure when planning launches in the US due to the unfavourable gross-to-net dynamics, weakened pricing leverage with US payers, and slower commercial uptake as insurers reassess cost-effectiveness due to the tariffs. Research and development budgets are already under pressure, and may be further strained as pharmaceutical companies may have to divert budget to firefight the impact of the tariffs. This could hinder innovation and pipeline investment, reducing the much-needed pace of therapeutic innovation across the industry. Earlier in the year, the US administration did signal tariffs for pharmaceutical imports could become a real possibility; this was met with proactive US investment from leading pharmaceutical companies to onshore manufacturing in the US to reduce exposure. Most recently, in July 2025, Biogen announced a $2bn investment into North Carolina, strengthening its US manufacturing position. Other pharmaceutical companies such as Johnson & Johnson, AstraZeneca, and Eli Lilly have also increased their investment in US manufacturing, with investments of $55bn, $50bn, and $27bn, respectively. Ultimately, the recent US-EU trade deal has increased the level of uncertainty within the pharmaceutical industry, raising concerns about the potential of tariffs increasing past 15% in the future. A once-shielded sector is facing a geopolitical shift, leaving the pharmaceutical industry vulnerable to global volatility. "New US-EU trade deal on tariffs ends pharma's geopolitical immunity" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
6 minutes ago
- Yahoo
Jackson Parish Hospital teams up with TruBridge to support financial operations
Jackson Parish Hospital, a critical access facility in Louisiana, US, has re-established its partnership with healthcare solutions company TruBridge to enhance its financial operations. With Under this strategic alliance, the 25-bed facility will implement TruBridge's technology driven, Complete Business Office (CBO) services. This move aims to improve the hospital's operational efficiency and financial health, encompassing revenue cycle management, billing, coding and claims management. The decision to return to TruBridge comes after a period of collaboration with another vendor since 2019. Jackson Parish CEO John Morgan said: 'The expertise at TruBridge is unlike any other that we experienced elsewhere. 'We see them as a leader in the community and critical access space and believe they understand our needs.' This renewed partnership builds upon a previous seven-year relationship. TruBridge is known for improving fiscal sustainability and securing efficient and accurate claims processing for health systems across the US. Its CBO services provide hospitals, ranging from critical access to 400-bed facilities, with solutions to stabilise operations, optimise cash flow, and achieve financial outcomes. TruBridge Financial Health general manager Merideth Wilson said: 'We are pleased to partner with Jackson Parish Hospital once again. Our shared mission to empower communities through fiscal sustainability is central to our relationship. 'Strong financial outcomes are integral to patient outcomes, and we're committed to helping communities thrive.' Earlier this year, TruBridge unveiled a partnership that integrated Microsoft Dragon Copilot with its electronic health record solution, aimed at boosting operational efficiency for hospitals and health systems throughout the US. Prior to this, Lady of the Sea General Hospital entered into a collaboration with TruBridge, focusing on enhancing patient care and the revenue cycle. "Jackson Parish Hospital teams up with TruBridge to support financial operations" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
